Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | WDR5 | P61964 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.53 |
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | PPARD | Q03181 | 3/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8955728 | 0.93 | HRH3 (0.57) | KMT2ACYP2D6DRD2DRD4LMNA | |
| SCHEMBL2096611 | 0.90 | KMT2A (0.62) | KMT2ACYP2D6DRD2DRD4LMNA | |
| SCHEMBL715593 | 0.86 | ALDH1A1 (0.54) | — | |
| SCHEMBL9808215 | 0.86 | LMNA (0.67) | KMT2ACYP2D6DRD2DRD4LMNA | |
| SCHEMBL1685432 | 0.84 | DRD2 (0.62) | KMT2ACYP2D6DRD2DRD4LMNA | |
| SCHEMBL10458289 | 0.82 | LMNA (0.59) | KMT2ACYP2D6DRD2DRD4LMNA | |
| SCHEMBL9774806 | 0.82 | DRD2 (0.60) | KMT2ACYP2D6DRD2DRD4LMNA | |
| SCHEMBL2096242 | 0.82 | WDR5 (0.59) | KMT2ACYP2D6DRD2DRD4LMNA | |
| Methyl Alcohol SCHEMBL27541418 | 0.81 | KMT2A (0.71) | KMT2ADRD2DRD4LMNAMAPK1 | |
| Sulfamate SCHEMBL9451417 | 0.81 | KMT2A (0.54) | KMT2ACYP2D6DRD2DRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4112599-A1 | KEY INTERMEDIATE FOR SYNTHESIZING PROSTAGLANDIN COMPOUNDS AND PREPARATION METHOD THEREFOR | SHENZHEN CATALYS TECHNOLOGY CO., LTD. (CN) | 2023-01-04 | — | — | EP | disclosed |
| US-7135466-B2 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-21 | — | — | US | disclosed |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-0044940-B1 | AMINO-DESOXY-1.4;3.6-DIANHYDRO-HEXITE NITRATES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | Dr. Willmar Schwabe GmbH & Co. (DE) | 1984-09-19 | — | — | EP | disclosed |
| US-4363805-A | TREATMENT OF CORONARY DISEASE | FIRMA WILLMAR SCHWABE (DE) | 1982-12-14 | — | — | US | disclosed |
| EP-0044940-A1 | Amino-desoxy-1.4;3.6-dianhydro-hexite nitrates, processes for their preparation and pharmaceutical compositions | Dr. Willmar Schwabe GmbH & Co. (DE) | 1982-02-03 | — | — | EP | disclosed |
| US-4017631-A | MICROBIOCIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1977-04-12 | — | — | US | disclosed |
| US-3991202-A | ANTIMICROBIALS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | KMT2A 2022/4885CYP2D6 2982/4885DRD2 621/4885 |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | KMT2A 2006/4885CYP2D6 2504/4885DRD2 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.